Exploring pyrazolines as potential inhibitors of NSP3-macrodomain of SARS-CoV-2: synthesis and in silico analysis
researchers present the synthesis of new and potential anti-viral pyrazoline compounds.
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Chinese researchers:
GZNL-P36 is a promising drug candidate for COVID-19 targeting a conserved viral enzyme, showing broad antiviral and anti-inflammatory effects.
Mouse trials: it reduces viral load, inflammation, and lung damage
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo
Researchers at The University of Hong Kong developed TMP1, an oral drug blocking coronavirus entry and replication.
Tested in mice and hamsters, it was effective against SARS-CoV-2 variants and drug-resistant strains.
Low dose rapamycin in a study was shown to increase interferon antiviral response. Participants reported lower rates of infections for 1 year. Improved T cell response. This drug is being trialed for . Amy Proal PhD 🧵
“Low dose rapamycin in a study was shown to increase interferon antiviral response. Participants reported lower rates of infections for 1 year. Improved T cell response. This drug is being trialed for #LongCovid. Amy Proal PhD @microbeminded2 🧵”
Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19
Shionogi just announced that their antiviral pill, ensitrelvir, significantly prevents COVID transmission!
Participants took the antiviral after known exposure.
Obeldesivir for COVID-19 Is Safe, Reduces Time to Symptom Relief in High-Risk Patients
My note: Would like to see study on this drug with endpoints like time to recovery, severity of symptoms, long-term follow-up for post-acute symptoms. Not holding my breath. This is, after all, Giliad, the maker of remdesivir. Still, potential early treatment option here:
465 adults received either obeldesivir or a placebo for 5 days. The results showed that those on obeldesivir had a 0% hospitalization rate and lower mortality compared to 0.5% in the placebo group.
Patients taking obeldesivir also experienced quicker symptom relief and greater reductions in the virus levels. Overall, the drug was found to be generally safe and well-tolerated.
Metformin suppresses SARS-CoV-2 in cell culture - PubMed
Anti-Viral Impact of Metformin “When AMPK was activated in Calu3 and Caco2 cell lines using metformin, there was a remarkable suppression of SARS-CoV-2 infectious titers, with up to 99% reduction observed in infected cells.”
Metformin suppresses SARS-CoV-2 in cell culture
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Next generation medicines in fight against Covid:
Focusing specifically on the receptor-binding domain (RBD) rather than the entire SARS-CoV-2 spike protein provides enhanced, long-lasting protection against viral mutations
INCLUSION OF
“INCLUSION OF MEGLUMINE ACRIDONE ACETATE (MA): CYCLOFERON
- FIBRINOLYTICS FOR CHRONIC COVID (LONG COVID) MDR (MULTI-DRUG-RESISTANT) WITH BIOFILMS/RESERVOIRS Protocol TenofovirDF/Emtricitabine + Sofosbuvir + MA: Cycloferon + Fibrinolytics Shows better results than Antivirals alone”
A dual inhibitor of PIP5K1C and PIKfyve prevents SARS-CoV-2 entry into cells
“the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells.”
the development of new small molecule-based antiviral candidates is imperative to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual PIKfyve and PIP5K1C inhibitor, as a new chemical agent that inhibits SARS-CoV-2 entry into host cells.
I'm on Tivicay (dolutegravir) and Truvada (emtricitabine/tenofivir) which I know at least one of my mutuals (HIV-) has been on for Long Covid specifically.
Study unveils novel treatment for blocking SARS-CoV-2 entry into cells
Professor Kyungjae Myung and his research team in the Department of Biomedical Engineering, affiliated with the IBS Center for Genomic Integrity, have discovered UNI418, a compound that effectively prevents the penetration of the coronavirus. This compound works by regulating dielectric homeostasis, thereby inhibiting the virus's entry into human cells. The paper is published in the journal Experimental & Molecular Medicine.
Professor Kyungjae Myung and his research team in the Department of Biomedical Engineering, affiliated with the IBS Center for Genomic Integrity, have discovered UNI418, a compound that effectively prevents the penetration of the coronavirus. This compound works by regulating dielectric homeostasis, thereby inhibiting the virus's entry into human cells. The paper is published in the journal Experimental & Molecular Medicine.
FDA Could Soon Limit Use of Only Drug for COVID Prevention
Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial | Invivyd
PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in Exploratory Analysis Ongoing Phase 3 Clinical Trial May be useful for PRE-EXPOSURE PROPHYLAXIS (Prep) in immunocompromised & immunocompetent
Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out
From reporter Jason Mast: “3 yrs ago, the Biden Administration announced a $3.2B plan to build antivirals for Covid and whatever pandemic nature might throw at us next
Most of the plan was never enacted. And what was built — 9 antiviral centers — may soon be dismantled”
Predictive Assessment of the Antiviral Properties of Imperata cylindrica against SARS‐CoV‐2
Imperata cylindrica or compounds show promise against COVID-19.
Tabanone, in particular, could inhibit a key viral protein and is considered safe, offering hope for new treatments.
Commonly known as “speargrass,” “cogongrass,” “alang-alang” or “kunai grass,” Imperata cylindrica is a member of the Poaceae family.
“The existing therapeutic alternatives have presented various setbacks such as low potency, poor pharmacokinetic profiles, and drug resistance. The need for alternative therapeutic options cannot be overemphasized. Plants and their phytochemicals present interesting characteristics that make them suitable candidates for the development of antiviral therapeutic agents. This study aimed to investigate the antiviral potential of Imperata cylindrica (I. cylindrica). Specifically, the objective of this study was to identify I. cylindrica phytochemicals that display inhibitory effects against SARS-CoV-2 main protease (Mpro)”
People living with HIV with the Omicron variant infection have milder COVID-19 symptoms: results from a cross-sectional study - AIDS Research and Therapy
PEOPLE LIVING with HIV with the OMICRON variant INFECTION have MILDER COVID-19 SYMPTOMS
Results from a cross-sectional study
Scientists Race To Perfect New Oral COVID-19 Treatment Poised To Replace Paxlovid